**Pterocarpus marsupium** Roxb. heartwood extract synthesized chitosan nanoparticles and its biomedical applications

Anupama Ammulu Manne¹, Vinay Viswanath K.¹, Ajay Kumar G¹, Ushakiranmayi Mangamuri² and Sudhakar Podha*¹

**Abstract**

**Background:** The point of the present investigation was to blend effective chitosan nanoparticles (CNPs) loaded with *Pterocarpus marsupium* (PM) heartwood extract and evaluate its biomedical applications. Various plant extract concentrations (PM-CNPs-1, PM-CNPs-2, PM-CNPs-3) are used to synthesize chitosan nanoparticles and optimized to acquire a stable nanoparticle formulation. The entrapment efficiency and in vitro release studies of the plant extract encapsulated in CNPs are estimated. The PM-loaded CNPs were characterized by X-ray diffraction, dynamic light scattering (DLS), Fourier transform infrared spectroscopy (FT-IR), scanning electron microscopy (SEM), and transmission electron microscopy (TEM). The synthesized chitosan nanoparticles were evaluated for their alpha-amylase inhibitory activity and inhibition of albumin denaturation activity.

**Results:** The XRD pattern of PM-CNPs shows less number of peaks at low intensity due to the interaction of chitosan with sodium tripolyphosphate. The FT-IR spectrum with peaks at 1639.55 and 1149.02 cm⁻¹ confirms the formation of chitosan nanoparticles. The size of the nanoparticles ranges between 100 and 110 nm with spherical shape illustrated by SEM and TEM analysis. The nanoparticle formulation with 10% plant extract concentration (PM-CNPs-2) showed optimum particle size, higher stability, enhanced entrapment efficiency, and sustained drug release characteristics. Synthesized chitosan nanoparticles have shown a significant increase in alpha-amylase inhibition and appreciable anti-inflammatory activity as measured by inhibition of protein denaturation.

**Conclusions:** The investigation reports the eco-friendly, cost-effective method for synthesizing chitosan nanoparticles loaded with *Pterocarpus marsupium* Roxb. heartwood extract.

**Keywords:** Chitosan nanoparticles, *Pterocarpus marsupium*, Alpha-amylase inhibitory activity, Anti-inflammatory activity

**Background**

Nanotechnology is the new science dealing with nanometer (nm) size, and nanoparticles (NPs) are one of the nanotechnology building blocks [1–3]. Nanotechnology combined with polymers has recently captivated immense interest in many fields including the pharmaceutical industry and medical field. NPs are the nanometer-ranging stable colloidal particles, i.e., from 10 to 1000 nm [4]. They show unusual physical and chemical properties, owing to their smaller size and larger surface area. Nanoparticles can be made from naturally occurring polymers like protein, polysaccharide or synthetic polymer like polystyrene. Nanoparticles made from natural polymers, by comparison, give both mild and easy preparation procedures without using organic solvent and higher shear force. Due to their intrinsic biological properties, chitosan nanoparticles have gained significant interest in the current scenario over the past years.

Chitosan nanoparticles (CNPs) are used in a range of various products and applications, ranging from medicinal,
drug delivery, tissue engineering, and food processing to bio-sensing, immobilization of enzymes, fuel cell development, and wastewater treatment [5]. Chitosan [poly(b-1/4)-2-amino-2-deoxy-D-glucopyranose] is a biopolymer which is a chitin derivative, extracted from the shellfish exoskeleton [6–8]. Chitosan has properties forming a film, fiber, and micro/nanoparticle, for its abundance, low cost of manufacturing, biodegradability, biocompatibility, reusable, and non-toxic nature. Because of their capacity to provide safety and stability, chitosan nanoparticles were used in the delivery of active components. Recently, extensive research has been carried out on chitosan nanoparticles to target biomolecules including anticancer chemotherapy [9], antibiotics [10], vaccines [11], peptides, genes [12], etc.

Polymers like chitosan nanoparticles are ideal shielding agents and can be used to deliver active ingredients. To date, CNPs ranging from few to several hundred nanometers have been manufactured using chemosynthetic techniques such as microemulsion, oil-water emulsion, spray-drying, precipitation, complex formation of polyelectrolytes, and methods of desolvation [13]. Nevertheless, due to the high solution viscosity and coiled nature of high molecular weight chitosan (HMWC), these synthetic techniques result in the creation of microparticles of more than 1000 nm. The entry of drug-charged particles into cells with pore sizes below 1000 nm in vivo is severely limited. It was calculated that the efficiency of cellular absorption of polymeric particles with a diameter of less than 1000 nm was 2.5–250 times greater than particles exceeding the nanometer scale [14]. Chemosynthetic techniques often rely on stabilizing agents such as polyethylene glycol (PEG), polyvinyl alcohol, and succinate D-alpha-tocopheryl poly (ethylene glycol) [15]. Such additional surface stabilizers significantly improve the half-life of nanoparticles by enhancing the longevity of NPs in the blood, which can induce nanotoxicity [16].

Eventually, regulating the size and shape of nanoparticles by enhancing current physical-chemical techniques was seen as a priority for material scientists to reduce, size-oriented limitations of polymeric nanoparticles. In this context, green nanotechnology, a well-established interdisciplinary nanoscience branch, has shown huge potential for creating nanostructures that are strictly within the range of a few nanometers, using biological systems like plants, fungi, and bacteria [17, 18]. Cross-linking chitosan (CS) with sodium tripolyphosphate (TPP) is a moderate, efficient approach for achieving CNPs. The nanoparticles are formed by the ionic gelation method, where electrostatic interaction between positively charged CS and negatively charged TPP molecules are cross-linked to form a chitosan nanoparticle.

Chitosan nanoparticles were loaded with various plants such as *Arrabidaea chica* [19], *Mentha longifolia* [20], *Leucas aspera* [21], and others. The physicochemical properties of chitosan nanoparticles such as size, surface area, cationic composition, effective functional groups, high permeability towards biological membranes, non-toxicity to individuals, cost efficiency, higher encapsulation performance and/or by mixing with other compounds and wide-ranging antifungal and antimicrobial activities have resulted in increased use in biomedical applications [22–25]. Thus, due to the extensive applications, chitosan polymer was chosen for the present research.

*Pterocarpus marsupium* plant belongs to the Fabaceae family and because of its diverse biological activities since ancient times it has been used in India and its neighboring countries. All parts of the plant are used as primitive home remedies against various human diseases. This was commonly used in homeopathic medicine, Unani systems, and ayurvedic [26, 27]. It is also commonly referred to as Malabar kino or Indian kino tree or Vijayasar, it is a medium to large deciduous tree which can grow up to 30 m (98 ft) tall [28, 29]. This is native to India, Nepal, and Srilanka. Heartwood (stem bark) is golden-yellow in color, possessing anti-inflammatory, astringent, anti-inflammatory, hypertriglyceridemic, cardiotoxic, wound healing, hepatoprotective function, and as a potent COX-2 inhibitor [30–33]. The plant *P. marsupium* was recognized as a very rich source of flavonoids and polyphenolic substances by earlier researchers [34]. All of *P. marsupium* functional phytoconstituents were thermostable. An active compound, epicatechin, was detected from the PM bark ethanol extract and the presence of three phenolic compounds pterostilbene, pterosupin, and marsupin as anti-diabetic agents in ethylacetate-soluble portions of aqueous extract of PM heartwood was reported [35]. Traditionally different plants have been used as anti-inflammatory agents. In Indian medicine *P. marsupium* was used from ancient times to treat burns, psoriasis, wounds, odontalgia, etc. [36]. The most significant biologically active ingredients in stem bark were terpenoids, saponins, tannins, alkaloids, flavonoids, and phenolic compounds. Due to various pharmacological activities, the plant *Pterocarpus marsupium* was taken in the present research.

The current research has been conducted to formulate and establish strategies to increase the therapeutic potential of standardized *Pterocarpus marsupium* heartwood extract using CNPs as carriers. The parameters have been modified to produce the optimal output of NPs. Introducing nanotechnology to plant extracts has provided a beneficial strategy for herbal medicinal products, taking into account the several features to be offered by nanostructured systems includes increasing solubility, pharmacological activity, bioavailability, safety from toxicity, controlled delivery, and safety from...
physical and chemical degradation [37, 38]. At present, processes in nanotechnology involving medicinal plants have produced several novel delivery methods, including polymeric nanoparticles. Those made from biocompatible and biodegradable polymers such as chitosan (CS) provide an alternative for sustained drug delivery [39]. These prepared green synthesized chitosan nanoparticles were characterized for size and morphology, drug entrapment efficiency, and drug release studies. These are evaluated for their anti-diabetic and anti-inflammatory activities.

Methods
Preparation of aqueous extract
The plant *Pterocarpus marsupium* Roxb. heartwood was collected from in and around Tirupati area and authenticated by Dr. K. Madhava Chetty, Assistant Professor, Department of Botany, Sri Venkateswara University, Tirupati (voucher no. 1587 has been deposited in a herbarium), dried PM heartwood was ground to fine powder, and 20 g of which was boiled in 100 ml of distilled water for 20 min. The obtained aqueous extract was then cooled and filtered using Whatman No. 1 filter paper, and kept in the refrigerator for further use.

Synthesis of nanoparticles
Chitosan nanoparticles were prepared by ionic gelation method [40]. Chitosan solution was prepared by adding 40 mg of chitosan (deacetylation degree ≥ 85%, M) to 1% (v/v) acetic acid slowly in smaller amounts for higher solubility in acidic medium. By using a digital homogenizer the solution was continuously stirred at 7000 rpm to obtain a homogeneous solution. The CS solution should maintain a pH of 5. Various concentrations of 5%, 10%, and 15% (PM-CNPs-1, PM-CNPs-2, PM-CNPs-3) of plant aqueous extract was added concerning to the chitosan concentration to the homogenous solution to obtain optimized nanoparticles. For cross-linking of chitosan as nanoparticles, an ionic crosslinking agent, sodium tripolyphosphate (TPP) was used, 8 ml of 0.1% TPP solution prepared in distilled water was introduced in dropwise to chitosan solution while homogenizing at a constant speed of 7000 rpm at room temperature for 2 h. Finally, the PM-CNPs so formed were separated from the solution by centrifugation at 15000 rpm for 30 min and freeze-dried to obtain nanoparticles in powder form.

Characterization of nanoparticles
X-ray diffraction (XRD) technique was used to classify the prepared PM-CNPs by using an X-ray diffractometer (Miniflex 600 Powder XRD, Osmania University). The calculation was carried out at a scanning speed of 50 S⁻¹ and within the scanning range of 10–80.

Fourier transform infrared spectroscopy
Fourier transform infrared spectroscopy was executed to analyze the formation of chitosan nanoparticles. The spectra of the considerable number of test samples (PM, CNPs, PM-CNPs) were recorded spectrometrically (Shimadzu FT-IR spectrophotometer) by KBr pellet development at room temperature. The range was kept in the range of 4000 and 400 cm⁻¹ at the resolution of 4 cm⁻¹.

Zeta potential, particle size, and PDI
The particle size and zeta potential of PM-CNPs were analyzed using a laser light scattering-based particle size analyzer (Zetasizer NS 3000, Malvern Instruments). The analysis was performed in triplicate manner, and average values with standard deviation were recorded.

Shape and surface morphology
The morphology of the arranged PM-CNPs was analyzed by scanning electron microscopy (SEM), using Zeiss SEM machine and transmission electron microscopy (TEM) using FEI-Tecnai G2 20 Twin, VIT University. The test sample (CNPs and PM-CNPs) for SEM investigation was set up by placing the filtered lyophilized nanoparticles onto the network, permitted to dry under a mercury light for SEM analysis after 10 min of drying. Test for TEM investigation was set up by placing a little drop of nanoparticle suspension on a carbon-covered copper network and enabling water to dissipate in a vacuum dryer. The grid containing PM-CNPs was scanned for TEM images.

Entrapment efficiency
The measure of PM encapsulated in the nanoparticles was controlled by UV spectrophotometry (Shimadzu UV-160 spectrophotometer, Kyoto, Japan). Each sample containing various concentrations of PM extract was centrifuged at 15000 rpm for 30 min and the supernatants are analyzed for absorbances at λmax of 279 nm using a UV spectrophotometer [41]. Values of absorbances acquired were quantified in mg of the plant extract present in the supernatant. This percentage of plant extract entrapped was calculated with the initial amount of the PM in the nanoparticles. Encapsulation efficiency of plant extract was determined by the following equation

\[
EE(\%) = \frac{\text{mass of initially added drug} - \text{mass of free drug}}{\text{mass of initially added drug}} \times 100
\]

The influence of plant extract concentration on EE was performed. The optimized nanoparticle formulation was taken for further in vitro drug release studies.

In vitro drug release studies
Studies of in vitro drug discharge were conducted using the technique of tube dialysis for the prepared formulations.
Two milligrams of freeze-dried PM-CNPs-2 were spread into the individual dialysis tube (MW 12,000 Da, Himedia) in 10 ml of phosphate buffer saline. The sealed dialysis bag was immersed in a 30 ml PBS (pH 7.4) buffer at 100 rpm at room temperature with constant stirring. A 2 ml aliquot was collected at regular time intervals and a similar quantity of PBS was added to the release medium. The aliquots were evaluated as a function of time using a UV spectrophotometer for the drug release concentration. The drug release concentration has been determined by using the following equation

\[
\text{Drug release} \% = \frac{\text{mass of encapsulated drug} - \text{mass of release drug}}{\text{mass of encapsulated drug}} \times 100
\]

**Assay of α-amylase inhibition**

Alpha-amylase inhibitory activity of PM incorporated chitosan nanoparticles was examined by employing the method determined by Poongunran [43]. Quickly, 100 μl of the integrated chitosan nanoparticles (PM-CNPs-2) were allowed to react with 200 μl of α-amylase and 100 μl of 2 mM phosphate buffer (pH 6.9). To which 100 ml of 1% starch solution was added and incubated for 20 min. The equivalent was employed to act as control where 200 μl of the enzyme was substituted with buffer. After incubating for 10 min, 500 μl of the DNS reagent was added to both control and test. They were subjected to boiling in a water bath for 5 min. The optical density was recorded at 540 nm utilizing a spectrophotometer. The percentage inhibition of α-amylase enzyme was determined by using the following formula

\[
\text{Inhibition} \% = 100 \times \left( \frac{\text{Control} - \text{Test}}{\text{Control}} \right)
\]

**Inhibition of protein denaturation**

The synthesized compounds are tested for anti-inflammatory activity using the albumin denaturation inhibition method [44]. The standard drug (diclofenac sodium) and synthesized nanoparticles (PM-CNPs-2) were dissolved in dimethylformamide (DMF) and diluted with phosphate buffer (0.2 M, pH 7.4). The final concentration of DMF was < 2.5% in all alternatives. Test solution (1 ml) containing different nanoparticle concentrations was mixed in phosphate buffer with 1 ml of 1 mM albumin solution and incubated in the BOD incubator at 27 °C ± 1 °C for 15 min. Denaturation was induced by 10 min in a water bath keeping the reaction mixture at 60 °C ± 10 °C. The turbidity at 660 nm (UV-visible spectrophotometer, Shimadzu) was evaluated after cooling. The percentage of albumin denaturation inhibition was calculated from the control, where no drug was added. All the experiments were conducted in triplicate.

**Statistical evaluation**

All results are expressed as mean ± SEM (n = 6). IC₅₀ values were calculated by applying a suitable regression analysis of the mean inhibitory values.

**Results**

**X-ray diffraction**

Figure 1 represents the pattern of chitosan nanoparticles loaded with PM extract in X-ray powder diffraction. Less noticeable peaks with very low intensity in the diffractogram of PM-CNPs showing a complex network structure of interpenetrating polymer chains of CS cross-linked with one another by TPP counter ions. While this diffractogram with lower peaks showed the formation of chitosan nanoparticles with heavy interaction between the counter-ions of chitosan and TPP.

**Zeta potential, particle size, and PDI**

The ZP represents the superficial electrical charge of particles and is determined by the composition of the particles and the dispersion media. This parameter is used as
an index of NP stability. The electronic repulsion among particles can significantly affect the stabilization of the suspended particles. Consequently, a higher absolute zeta-potential value suggests a more stable suspension, while a lower value means colloidal instability, which may lead to aggregation of nanoparticles. Nanoparticles with a zeta potential > ± 30 mV are stable in suspension, as the surface charge inhibits particle aggregation [45].

The nanoparticle formulation, PM-CNPs-2 resulted in enhanced effectiveness of drug trapping with optimum mean particle size and PDI for chitosan nanoparticles. Thus PM-CNPs-2 with 57.3 mV and with an optimum particle size of 676± 2.76 nm are stable compared to other plant extract concentration-loaded nanoparticles as shown in Figs. 2 and 3.

FT-IR spectroscopy analysis of chitosan nanoparticles

Chitosan nanoparticles were synthesized by cross-linking chitosan and tripolyphosphate (TPP). FT-IR studies of chitosan nanoparticles (CNPs), plant extract (PE), and PM extract-loaded chitosan nanoparticles (PM-CNPs) were performed to characterize the chemical nature of the nanoparticles as shown in the Fig. 4. The present studies showed sharp absorption peaks at 3430.64, 2956.97, 1629.90, 1149.01, and 1035.81 cm⁻¹ for chitosan nanoparticles (Fig. 4b) and intense peaks were found at 3402.54, 2924.18, 1639.55, 1464.02, 1377.22, 1149.01, 1047.36 cm⁻¹ for PM-CNPs (Fig. 4c). FT-IR study for Pterocarpus marsupium stem bark aqueous extract showed sharp peaks at 3437.26, 3429.56, 2924, 2232.70, 2341.06, 1618.02, and 1529.90 cm⁻¹ (Fig. 4a). The results confirmed that the biomolecules of PM stem bark extract were loaded in chitosan nanoparticles.

Shape and surface morphology

Figure 5 represents the SEM images of P. marsupium-loaded and P. marsupium-unloaded chitosan nanoparticles at 10 μm scale bar. The SEM pictures confirm the formation of chitosan nanoparticles. The images clearly show the spherical shape of the nanoparticles. The TEM image also portrays the spherical shape of the nanoparticles as shown in Fig. 6.

Entrapment efficiency

Entrapment efficiency of PM-loaded nanoparticles was estimated and performed in triplicate. The effect of the amount of PM on EE is shown in Table 1. The formulation of nanoparticles showed an improvement in the effectiveness of trapping with a rise in the
Fig. 3 Particle size distribution of chitosan nanoparticles (CNPs) loaded with different *P. marsupium* stem bark extract concentrations. **a** PM-CNPs-1, **b** PM-CNPs-2, **c** PM-CNPs-3.

Fig. 4 FT-IR spectrums of **a** *Pterocarpus marsupium* (PM) aqueous stem bark extract, **b** chitosan nanoparticles (CNPs), and **c** *Pterocarpus marsupium*-loaded chitosan nanoparticles (PM-CNPs).
concentration of drugs. The entrapment efficiencies of PM-CNPs-1, PM-CNPs-2, and PM-CNPs-3 are 68.87 ± 3.1, 82.78± 5.67, and 86.76± 5.43.

**In vitro drug release studies**
The in vitro PM release from PM-CNPs-2 is demonstrated in Fig. 7 from which it was proven that the release of the drug from chitosan nanoparticles was sustained throughout 15 h with a cumulative release of 37.5%.

**Effect on α-amylase inhibition**
Figure 8 demonstrates the activity of PM-CNPs-2 on inhibiting amylase. The percentage inhibition of α-amylase by the chitosan nanoparticle synthesized with *P. marsupium* was researched within a concentration range
of 20–100 μg/ml and 62.46 was found to be the IC₅₀ value as shown in Table 2.

**Effect on protein denaturation**

Figure 9 illustrates the in vitro anti-inflammatory activity of PM-CNPs-2 on inhibiting protein denaturation. The minimum inhibition observed at 20 μg/ml concentration by the synthesized nanoparticles is 19.23 ± 1.07%. The IC₅₀ was found to be 92.76 as shown in Table 3.

**Discussion**

**X-ray diffraction studies**

The XRD analysis shows the presence of chitosan nanoparticles with characteristic diffraction peaks (Fig. 1). The XRD pattern of chitosan nanoparticles synthesized from *P. marsupium* Rox.b heartwood extract showed a large diffraction peak at 2θ range of 22.56°, respectively, which is a standard fingerprint of CNPs. The lower intensity exhibited by PM-CNPs diffraction peaks shows that they are amorphous in nature. In the XRD patterns of PM-loaded chitosan nanoparticles, the absence of any other diffraction peaks, corresponding to impurities is observed, which indicates their purity. The rate of diffraction peaks is reduced in the case of chitosan nanoparticles, as a result of transforming crystallized chitosan into amorphous form after being cross-linked with tripolyphosphate. In our analysis, the diffraction peak of pure chitosan usually observed at 22.04° [46] has shifted slightly to a higher value of 22.56°, and this can be due to the cross-linking of chitosan nanoparticles with TPP and the amorphous chitosan structure.

**Zeta potential, particle size, and PDI**

Increasing the drug quantity improved the nanoparticle particle size and PDI. Chitosan nanoparticles are synthesized by linking cationic ammonium groups of chitosan and anionic phosphate groups of tripolyphosphate (TPP). The surface charge on the chitosan nanoparticles are indicated by the number of unneutralized ammonium groups in chitosan. Since the number of positive charge groups of chitosan is more than the number of negative charges of TPP, the net charge on the chitosan nanoparticles is positive.

The average size, zeta potential, and polydispersity index of the chitosan nanoparticle formulations were evaluated by zeta sizer analysis as shown in Table 4. The average sizes of CNPs, PM-CNPs-1, PM-CNPs-2, and PM-CNPs-3 were 238 ± 145, 445 ± 2.43, 676 ± 2.76, and 547 ± 286 nm, respectively as shown in Fig. 3. Due to the interaction between the polymer and plant extract structure, the particle size increases with a rise in plant extract concentration. The value of the polydispersity index (PDI), varying from 0 to 1, determines the particle homogeneity. All formulations polydispersity index values ranged from 0.276 to 0.465. As observed in Fig. 2, the zeta potential values indicate that the surface of the chitosan nanoparticle without plant extract had a positive charge of 36.2 mV, and the plant extract-loaded chitosan nanoparticles at various plant extract concentrations (PM-CNPs-1, PM-CNPs-2, PM-CNPs-3) exhibited zeta potentials of 40.4, 57.3, 44.6 mV, respectively. The PM-CNPs had higher positive value ranges from 40.0 to 57.3 mV compared to CNPs (36.2mV), this is because of the rise in groups of positive charges on the surface of plant extract synthesized chitosan nanoparticles. The result showed that PM-CNPs-2 had a Zeta potential of 57.3 mV. The higher ZP indicates CNPs are relatively stable. The long amino groups seem likely to inhibit anion adsorption and hold the value of the electrical double layer thickness high, thus preventing aggregations.

**FT-IR spectroscopy analysis of chitosan nanoparticles**

Chitosan nanoparticles were synthesized by cross-linking chitosan and tripolyphosphate (TPP). FT-IR studies of chitosan nanoparticles, plant extract, plant extract-loaded chitosan nanoparticles were performed to characterize the chemical nature of the nanoparticles. The FT-IR analysis was carried out to determine the biomolecules specifically bound on the chitosan nanoparticles that were involved in the stabilization. FT-IR spectra of chitosan nanoparticles and PM-CNPs were prepared are represented in Fig. 4b, c showing the peaks of NH₂ and OH group stretching vibrations in chitosan.

---

**Table 1** Entrapment efficiencies of different concentrations of *Pterocarpus marsupium* heartwood extract

| Plant extract concentration (%) | Entrapment efficiency |
|---------------------------------|-----------------------|
| 2.5                             | 48.78± 2.71           |
| 5                               | 68.87± 3.1            |
| 10                              | 82.78± 5.67           |
| 15                              | 86.76± 5.43           |
| 20                              | 86.56± 5.32           |

---

![Fig. 7 Drug Release profile of Pterocarpus marsupium extract-loaded chitosan nanoparticles](image)
at 3430 and 3402 cm\(^{-1}\). The amount of water present in the chitosan nanoparticles provides an indication of its hydrophilic existence, which is consistent with the \(-\text{OH}\) and \(-\text{NH}_2\) bonding observed in the FT-IR spectrum of the chitosan nanoparticles between 3430.64 and 3402 cm\(^{-1}\) [47, 48]. In PM-CNPs, a shift was observed from 3430 to 3402 cm\(^{-1}\) and this peak at 3402 cm\(^{-1}\) is less wide, indicating reduced hydrogen bonding. The decreased binding of hydrogen was due to a more open framework arising from interconnection with biomolecules of *Pterocarpus marsupium* extract as well as TPP. Table 5 shows all the peaks of PM-CNPs and its functional groups.

The bands at 2924 cm\(^{-1}\) in both formulations (Fig. 4b, c) correspond to stretching vibrations of CH\(_3\) and CH\(_2\). The characteristic peak at 1629 and 1639 cm\(^{-1}\) (amide I) in CNPs and PM-CNPs, indicates the formation of nanoparticle due to the binding of proteins with O and N of those groups [49]. The presence of P=O peak can be observed at 1149 cm\(^{-1}\) in both CNPs and PM-CNPs, due to the prospective interaction of protonated amine/amide groups of chitosan and negatively charged polyphosphoric groups of sodium polyphosphate, which enables enhancing both inter and intramolecular interactions in CNPs [50]. The characteristic peaks at 1464 and 1377 cm\(^{-1}\) ascribes to the aldehyde groups in which hydroxyl end groups of heartwood extract was transformed after the oxidation reaction in PM-CNPs (Fig. 4c) formulation.

A peak at 1529 and 1618 cm\(^{-1}\) in *Pterocarpus marsupium* heartwood extract (Fig. 4a), represents the presence of the ketone and carboxylic acid group \(-\text{C}=\text{O}\), respectively, due to the presence of terpenoids, tannins, and flavonoids. The peak at 2341 cm\(^{-1}\) is due to the bending vibration of alkynes. The broad absorbance peak at 3437 cm\(^{-1}\) is correlated with the presence of hydroxyl functional groups in the phenolic and alcoholic compounds.

### Shape and surface morphology

The surface morphology of the CNPs and PM-CNPs was determined by SEM (Fig. 5). There was a large amount of nearly separated spherical nanoparticles as observed by Yang and Gan Q [51] and Wang [52]. The unloaded chitosan nanoparticles have a particle size of 80–90 nm and the size of PE-loaded chitosan nanoparticles is of 100–110 nm. Hence, the size of the nanoparticle increases by the addition of plant extract. Notably, the hydrodynamic diameter of particles measured by DLS was larger than the size calculated by microscopy generally due to the high capacity of CNPs to swell. In DLS, we obtain the particle hydrodynamic radius while we get an estimate of the observed area diameter by SEM. For DLS, as a distributed particle moves through a liquid medium, the solvent adheres to its surface through a thin layer of an electric dipole. This layer determines the particle movement throughout the medium.

Hydrodynamic diameter, therefore, gives us knowledge of the inorganic center along with the coating substance

**Table 2** Alpha-Amylase inhibitory activity by PM-CNPs-2

| Treatment          | Concentration (μg/ml) | Percentage of inhibition | IC\(_{50}\) |
|--------------------|-----------------------|--------------------------|------------|
| Chitosan nanoparticles | 20                   | 22.45 ± 1.21             | 62.46      |
| Loaded *Pterocarpus marsupium* | 40               | 34.67 ± 1.33             |            |
|                    | 60                   | 45.58 ± 1.53             |            |
|                    | 80                   | 54.76 ± 1.65             |            |
|                    | 100                  | 59.34 ± 1.63             |            |
| Acarbose           | 20                   | 21.23 ± 1.04             | 236.78     |
|                    | 40                   | 31.34 ± 1.68             |            |
|                    | 60                   | 44.65 ± 1.54             |            |
|                    | 80                   | 54.87 ± 1.67             |            |
|                    | 100                  | 66.32 ± 2.16             |            |

Values are expressed in terms of mean ± SEM (n = 6)
and the solvent layer bound to the surface as it passes under the influence of Brownian motion. At its core, DLS offers excellent statistics for an average size (by intensity), average poly-dispersity index (PDI), and a moderately peak-resolved statistical inversion distribution. While estimating size by SEM, this layer of hydration was therefore not present, so we only get information about the inorganic core. The variation occurs when DLS tests the diffusion in water, and even the particles of dust in the sample that may alter the readings. So in DLS study, we get a greater size of nanoparticles. TEM pictures also showed that PM-CNPs were spherical as shown in Fig. 6.

**Entrapment efficiency**

The entrapment efficiencies of PM-CNPs-1, PM-CNPs-2, and PM-CNPs-3 are 68.87 ± 3.1, 82.78± 5.67, and 86.76± 5.43 as shown in Table 1. Beyond PM-CNPs-3 extract concentration, entrapment efficiency almost remained constant. This can be explained by the fact that initially nanoparticles were not saturated with the drug; the increase in drug concentration increased the availability of the drug for encapsulation. An increase in the concentration of drug encapsulated increased the size of the nanoparticles. Further enhanced concentration of drug shows no further drug encapsulation, keeping the size of the particle constant. The size of the nanoparticle also influences the entrapment efficiency, as larger nanoparticles have a larger volume that can hold more amount of drug. Previous reports have also shown improved EE in ketoconazole-loaded CNPs with an increase in the mean particle size of the nanoparticles [53].

**In vitro drug release studies**

For drug release studies, PM-CNPs-2 has been chosen. UV-spectrophotometric assessment evaluated the amount of plant extract released from nanoparticles using the calibration curve. Chitosan nanoparticles imparted sustained release to the drug wherein the drug was released up to greater than 85% from PM-CNPs in 15 h. The release rates of PM-loaded nanoparticles showed an initial burst release [54] of about 50% in the starting 8 h with a subsequent release of 35% in the next 8 h at a slower pace. In the initial phase, the burst release was quickly released into the medium due to drug adsorption on the surface of the chitosan nanoparticles. In the next phase, the slow release was due to the slow degradation of chitosan nanoparticles by diffusing the release medium inside the NPs, allowing the diffusion of entrapped drugs through nanoparticle pores into the

| Treatment               | Concentration (μg/ml) | Percentage of inhibition | IC50  |
|-------------------------|-----------------------|--------------------------|-------|
| Chitosan nanoparticles  | 20                    | 19.23 ± 1.07             | 92.76 |
| Loaded Pterocarpus      | 40                    | 37.24 ± 1.36             |       |
| Marsupium               | 60                    | 49.37 ± 1.27             |       |
|                         | 80                    | 56.76 ± 1.65             |       |
|                         | 100                   | 63.52 ± 1.42             |       |
| Diclofenac sodium       | 20                    | 12.87 ± 1.02             | 157.43|
|                         | 40                    | 37.26 ± 1.47             |       |
|                         | 60                    | 56.35 ± 1.52             |       |
|                         | 80                    | 73.33 ± 1.68             |       |
|                         | 100                   | 89.90 ± 2.01             |       |

Values are expressed in terms of mean ± SEM (n = 6)
medium. The in vitro PM release from PM-CNPs-2 is demonstrated in Fig. 7 from which it was proven that the release of the drug from chitosan nanoparticles was sustained throughout 15 h with a cumulative release of 37.5%.

**Amylase inhibition**

Alpha-amylase is an enzyme involved in starch breakdown, and the inhibition of amylase activity is a further therapeutic target in controlling type II diabetes. Several studies centered on pterostilbene and (-epicatechin which were recognized as two main compounds in PM heartwood and bark responsible for anti diabetic effects. Antidiabetic drugs attack complex biochemical pathways including carbohydrate digestion. α-amylase and α-glucosidase are the main enzymes involved in the digestion of dietary carbohydrates into easily absorbable molecules. Inhibition of these enzymes is beneficial in reducing postprandial blood glucose spikes [55]. ZnO nanoparticles-loaded *Pterocarpus marsupium* extract was analyzed for alpha-amylase activity in a concentration range of 20–100 μg/ml, and the IC$_{50}$ was found to be 59.38 [56].

**Inhibition of protein denaturation**

Protein denaturation implies the loss of biological characteristics of protein molecules, their structure, and function. Therefore, any plant material that prevents protein denaturation may be an effective anti-inflammatory agent. Proven studies showed the effectiveness of *P. marsupium* extract towards the anti-inflammatory activity. Methanol and aqueous extracts of *Pterocarpus marsupium* showed similar anti-inflammatory potential determined by their IC$_{50}$ values of 45 ± 1.6 μg/ml, 45 ± 0.94 μg/ml, compared to 55 ± 0.24 μg/ml for diclofenac sodium [57]. *P. marsupium* methanol (50 mg/kg, b.wt) and aqueous extract (100 mg/kg, b.wt) was administered to carrageenan mediated rat paw edema model to test anti-inflammatory activity. Both the extracts were found to have significant anti-inflammatory activity [58, 59]. *P. marsupium* aqueous extract was found to decrease elevated inflammatory cytokine, TNF-α in NIDDM diabetic rats at doses of 100 mg/kg and 200 mg/kg, b.wt [60]. Anti-inflammatory therapy is promising for drugs or phytochemicals that are useful in stopping protein denaturation [61]. Phenolics and flavonoids present in plant extracts mediate the anti-inflammatory activity [62]. In this research, the chitosan nanoparticles noted a dose-dependent inhibition of protein denaturation, exhibiting its anti-inflammatory activity. The ability to inhibit protein denaturation helps to mitigate indirectly, and this can help to develop anti-inflammatory medicines.

**Conclusion**

The method used for the synthesis of chitosan nanoparticles using *Pterocarpus marsupium* is a novel, cost-effective, and ecofriendly for synthesizing CNPs compared to well-known established methods showing high particle yield at low concentration of plant extract. The synthesized CNPs are highly stable. The XRD analysis showed less intense peaks of PM-CNPs due to the cross-linking of chitosan nanoparticles and are highly stable. The XRD analysis showed less intense peaks of PM-CNPs due to the cross-linking of chitosan nanoparticles and are highly stable. The XRD analysis showed less intense peaks of PM-CNPs due to the cross-linking of chitosan nanoparticles and are highly stable. The XRD analysis showed less intense peaks of PM-CNPs due to the cross-linking of chitosan nanoparticles and are highly stable. The XRD analysis showed less intense peaks of PM-CNPs due to the cross-linking of chitosan nanoparticles and are highly stable.

**Table 4** Different indicated criterion results of chitosan nanoparticle formulations

| Formulation | Plant extract concentration (μl) | Zeta potential (Mv) | Particle size (nm) | PDI |
|-------------|---------------------------------|--------------------|-------------------|-----|
| CNPs        | 0                               | 36.2               | 238±7.1.45        | 0.276 |
| PM-CNPs-1   | 5%                              | 40.4               | 445±2.43          | 0.365 |
| PM-CNPs-2   | 10%                             | 57.3               | 676 ± 2.76        | 0.465 |
| PM-CNPs-3   | 15%                             | 44.6               | 547±2.86          | 0.343 |

**Table 5** FT-IR peaks of *Pterocarpus marsupium*-loaded chitosan nanoparticles and their respective assigned functional groups

| S. No. | FT-IR peaks in PM-CNPs (cm$_{-1}$) | Functional groups       |
|--------|-----------------------------------|-------------------------|
| 1.     | 3402.54                           | Presence of hydroxyl bond |
| 2.     | 2924.18                           | Stretching vibrations of CH$_3$ and CH$_2$ |
| 3.     | 1639.55                           | Presence of C=O stretch in an amide bond |
| 4.     | 1464.02                           | CH$_3$ and CH$_2$ deformations |
| 5.     | 1377.22                           | Symmetrical bending of CH$_3$ |
| 6.     | 1149.01                           | Presence of P=O peak     |
| 7.     | 1047.36                           | Stretching vibration of –C--O--
Authors’ contributions
MAA conducted the research and writing of the manuscript. AKG has assisted, analyzed the data, and performed initial drafting of the manuscript. VVK executed the experimental works and analyzed the data. UM gave assistance in the study administration. SP was responsible for designing the research and approving the final content of the manuscript. All the authors have read and approved the final manuscript.

Funding
Not applicable

Availability of data and materials
Not applicable

Ethics approval and consent to participate
Not applicable

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Biotechnology, Acharya Nagarjuna University, Nagarjuna nagar, Guntur, Andhra Pradesh 522510, India. 2Department of Botany and Microbiology, Acharya Nagarjuna University, Nagarjuna nagar, Guntur, Andhra Pradesh 522510, India.

Received: 6 February 2020 Accepted: 6 May 2020
Published online: 06 July 2020

References
1. Colvin VL, Schlamp MC, Alivisatos A (1994) Light-emitting diodes made from cadmium selenide nanocrystals and a semiconducting polymer. Nature 370:354–357. https://doi.org/10.1038/370354a0
2. Wang Y, Herron N (1991) Nanometer-sized semiconductor clusters: Materials synthesis, quantum size effects, and photophysical properties. J Phys Chem 95:525–532 https://doi.org/10.1021/j100155a009
3. Keutner J (2001) Nanoparticulate systems for brain delivery of drugs. J Adv Drug Delivery Reviews 47:65–81. https://doi.org/10.1016/s0169-409x(00)00122-8
4. Jafarizadeh-Malhiri H, Gha-Jahani MA, Berenjian A (2012) Potential applications of chitosan nanoparticles as novel support in enzyme immobilization. Am J Biochem Biotechnol 8:203–219. https://doi.org/10.3844/ajbbsp.2012.203.219
5. Schmid G (1992) Large clusters and colloids. Metals in the embryonic state. Chem Rev 92:1709–1727 https://doi.org/10.1021/ cr00160a002
6. Ye M, Lian X, Huaping T, Ming F, Jianliang L, Yang J, Zhonghua L, Yong C, Xiaohong H (2017) Chitosan membrane dressings toughened by glycerol to load antibacterial drugs for wound healing. Mater Sci Eng A 81:522–531. https://doi.org/10.1016/j.msec.2017.08.052
7. Nitta S, Kaketsu I, Iwamoto H (2015) Development of chitosan-nanofiber-based hydrogels exhibiting high mechanical strength and pH-responsive controlled release. Eur. Polym. J 67, 50–56 DOI: 10.1016/j.eurpolymj.2015.08.002
8. Castro S.P.M, Lizarraga Paulin E.G (2012) Chitosan a new panacea? Areas of application. In The Complex World of Polysaccharides. Intech: Luxembourg 3–46 DOI: https://doi.org/10.5772/51200.
9. Song H, Su C, Cui W, Zhu B, Liu L, Chen Z, Zhao L (2013) Folic acid-chitosan conjugated nanoparticles for improving tumor-targeted drug delivery. Biomed Res Int. Article ID 723158. DOI: 10.1155/2013/723153.
10. Bhatta R S, Chandrasan H, Chhonker Y S, Rath C, Kumar D, Mitra K, Shukla P K (2012) Mucocadhesive nanoparticles for prolonged ocular delivery of natamycin: in vitro and pharmacokinetics studies. Int J Pharma 432(1–2) 105–112 DOI: 10.1016/j.ijpharm.2012.04.060.
11. Harde H, Agrawal AK, Jain S (2014) Development of stabilised glucosaminoxylated chitosan nanoparticles using tandem crosslinking method for oral vaccine delivery. Nanomedicine 9(16):2511–2529. https://doi.org/10.2217/nmn.13.225
12. Alex S M, Rekha M R, Sharma C P (2011) Spermine grafted galactosylated chitosan for improved nanoparticle-mediated gene delivery. Int J Pharm 410(1–2) 1257–135. DOI: doi.org/10.1016/j.ijpharm.2011.02.067
13. Kumari A, Yadav SK, Yadav SC (2010) Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B: Biointerfaces 75:1–18. https://doi.org/10.1016/j.colsurfb.2009.09.001
14. Choudhari Y, Detane SV, Kulthe S S, Godhani C, Inamdar NN, Shirolikar SM, Borde LC, Mourya VK (2012) Low molecular weight palmitoyl chitosan: synthesis, characterization, and nanoparticle preparation. Adv Mater Lett 3(6):487–492. https://doi.org/10.1587/amlett.2012.icnano.203
15. Desai MP, Labhasetwar W, Victor E, Levy RJ, Amidon GL (1997) The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size-dependent. Pharm Res 14(11):1568–1573. https://doi.org/10.1023/a:1012126301290
16. Kumari A, Kumar V, Yadav S K (2012) Plant extract synthesized PLA nanoparticles for controlled and sustained release of quercetin a green approach. PLoS One 7(7):e41230. DOI: doi.org/10.1371/journal.pone.0041230.
17. Sahoo SK, Panyam J, Prabha S, Labhasetwar V (2002) Residual polynyl alcohol associated with poly (D, L-lactic-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release 92:105–114. https://doi.org/10.1016/s0168-3659(02)00127-x
18. Gupta A, Bonde S R, Gaiwad S, Ingle A, Gade A K, Rai M (2013) Lawsonia inermis mediated synthesis of silver nanoparticles: activity against human pathogenic fungi and bacteria with special reference to formulation of an antimicrobial nanogel. J Nanobiotechnol. DOI: 10.1049/i-jnbt.2013.0015.
19. Servat-Medina LV (2015) Chitosan–trisophosphorylphosphinate nanoparticles as Anadyosidea chico standardized extract carrier: synthesis, characterization, biocompatibility, and antioxidant activity. Foglio. Int J Nanomedicine 10: 3897–3909. https://doi.org/10.2147/JN38705
20. Abeer Ramadan Mohamed Abd El-Aziz, Monira Rashid Al-Othman, Mohammed Abobakir Mahmoud, Sheereen Mohamed Shehata, and Nahla Shadi Abadelazim 2018 Chitosan nanoparticles as a carrier for Mentha longifolia extract: synthesis, characterization and antifungal activity. Curr Sci 114 (10) DOI: 10.18520.
21. Devi C S, Tariq-Feb A and Shishodya E (2015) Encapsulation of Staphylokinase and Leucasparsa plant extracts using chitosan nanoparticles. Int J PharmTech Res 7 (4) 654–661.
22. Sahana V, Mehrotta A, Khakht R, Rawal P, Sharma SS, Pal A (2013) Synthesis of chitosan-based nanoparticles and their in vitro evaluation against pythopathogenic fungi. Int J Biol Macromol 62:667–683. https://doi.org/10.1016/j.ijbiomac.2013.10.012
23. Wang X, Du Y, Liu H (2004) Preparation, characterization and antimicrobial activity of chitosan–Zn complex. Carbohydr. Polym 56:21–61. https://doi.org/10.1016/j.carbpol.2003.11.007
24. Comadini E, De Moura MR, Mattoso LHC (2010) A preliminary study of incorporation of NPK fertilizer into chitosan nanoparticles. Express Polym Lett 4:509–515. https://doi.org/10.3144/expresspolymlett.2010.04
25. Brunel F, Guedard N E E and Moerschbacher B M (2013) Complexation of copper (II) with chitosan nanogels: toward control of microbial growth. Carbohydr. Polym. 92, 1348–1356 DOI: https://doi.org/10.1016/j.carbpol.2012.10.025
26. Gambire JS (1935) Flora of the Presidency of Madras. Adlard and Sons Ltd, London, UK.
27. Matthew K M (1983) The Flora of Tamil Nadu Carnatic. St. Josephs College, Tiruchirappalli, India. 1983
28. Abhishek N, Karunakar H (2017) Pharmacological profile of Pterocarpus marsupium with a note on its therapeutic activity. A Review. International Journal of Pharma and Chemical Research 3(1):32–37
29. Rout S D, Thatoi H N (2009) Ethnomedicinal practices of Kol tribes in Smililip biosphere reserve, Orissa, India. Ethnobotanical Leaflets 3:1 DOI: 10.5185/ajbbsp.2009/1153s1.
30. Kirikar B (1987) Indian Medicinal Plants. Materia Medica. 2nd Ed. Vol I. New Delhi 1826–7. 13.
31. Mochrie NC, Salunkie VR, Bhirse SB, Yadav AV (2007) Cardiotonic activity of aqueous extract of heartwood of. Pterocarpus marsupium 45(6):532–537
32. Manikani KS, Krishna V, Marimuthu RK, Vidyas SM, Singh SJ, Manohara VNI (2005) Evaluation of hepatoprotective activity of stem bark of Pterocarpus marsupium Roxb. Indian J Pharm 37(3):165. https://doi.org/10.4103/0253-7613.16213
characterized by pterostilbene, and its activity in healthy human volunteers. Planta Med 7(5):387–392. https://doi.org/10.1055/s-0029-1236561
34. Seshadri TR (1972) Polyphenols of *Pterocarpus* and *Dalbergia* woods. Phytochemistry 11(3):381–388
35. Chelkarbirt BK, Gupta S, Goda KD (1982) Functional 13 cell regeneration in the islet of pancreas in allixonan diabetic rats by epicarpein. Life Sci 31:2693–2697
36. Rastogi and Mehrotra (1982) Compendium of Indian medicinal plants. P1D New Delhi 1993:537
37. Garcia-Fuentes M, Alonso MJ (2012) Chitosan-based drug nanocarriers: where do we stand? J Control Release 161(2):496–504
38. Ajazuddin SS (2010) Applications of novel drug delivery system for herbal formulations. Fitoterapia 81(7):680–689
39. Bonfaccio BV, Silva PB, Ramos MA, Negri KM, Baub TM, Chorilli M (2014) Nanotechnology-based drug delivery systems and herbal medicines: a review. Int J Nanomedicine 9:1–15. https://doi.org/10.2147/IJNN.S2634
40. Loic B, Catherine L (2016) Interests of chitosan nanoparticles ionic cross-linked with triplyphosphate for biomedical applications. Prog Polym Sci 60:1–17. https://doi.org/10.1016/j.progpolymsci.2014.03.032
41. Bagalakshmji N and Hantha H (2017) Green synthesis and characterization of silver nanoparticles using *Pterocarpus marsupium* and assessment of its in vitro Anti-diabetic activity. American Journal of Advanced Drug Delivery ISSN 2321-547X.
42. Nguyen V C, Nguyen V B, Hsieh M F (2013) Curcumin-loaded chitosan/gelatin composite sponge for wound healing application. Int. J. Polym. Sci. 7:1–13 DOI: https://doi.org/10.1155/2013/106570.
43. Poongunran J, Perera HKI, Fernando WIT, Jayasinghe L, Sivakanesan R (2015) Antidiabetic effects of *Pterocarpus marsupium* and its potent anticancer action. Nanomaterials (Basel) 9(10):1423. https://doi.org/10.3390/nano9101423
44. Salunkha VR, Yadav AV, Shete AS, Kane SR, Kulkarni AS (2005) Anti-inflammatory activity of extracts of *Pterocarpus marsupium* and *Coccolina indica*. Indian Drugs 42(5):319
45. Agarwal M, Agarwal MK, Shrivastav N, Pandey S, Das R, Gaur P (2018) Preparation of Chitosan Nanoparticles and their In-vitro Characterization, Int J Life Sci Scient Res 4(2):1731–1720. https://doi.org/10.21276/jlsr.2018.4.2.17
46. Nagarwal RC, Singh PN, Kant S, Matti P, Pandit JK (2011) Chitosan nanoparticles of 5-fluourouracil for ophthalmic delivery: characterization, in vitro and in-vivo study. Chem Pharm Bull 59(2):272–278. https://doi.org/10.1248/cpb.59.272
47. Keogh JB, Woostton BW, Taylor CM, Janakievski F, Desilva K, Clifton PM (2010) Effect of glycomacroepide fractions on cholecystokinin and food intake. Br J Nutr 104(2):286–290. https://doi.org/10.1017/S000711451000280
48. Borbon AI, Pinheiro AC, Cerquerira MA, Rocha CMR, Avides MC, Quintas MAC, Vaincenta AAJ (2011) Food Eng 106:111
49. Leung MYK, Fung KP, Choy YM (1997) The isolation and characterization of chloramphenicol and ketoconazole. Colloids Surf. B: Biointerfaces 84(1):163–170. https://doi.org/10.1016/S0928-0967(16)31866-8
50. Chehroberty BK, Gupta S, Goda KD (1982) Functional 13 cell regeneration in the islet of pancreas in allixonan diabetic rats by epicarpein. Life Sci 31:2693–2697
51. Rastogi and Mehrotra (1982) Compendium of Indian medicinal plants. P1D New Delhi 1993:537
52. Garcia-Fuentes M, Alonso MJ (2012) Chitosan-based drug nanocarriers: where do we stand? J Control Release 161(2):496–504
53. Poongunran J, Perera HKI, Fernando WIT, Jayasinghe L, Sivakanesan R (2015) Alpha-glucosidase and alpha-amylase inhibitory activities of nine Sri Lankan anti-diabetic plants. British Journal of Pharmaceutical Research 5(5):365–374
54. Salunkha VR, Yadav AV, Shete AS, Kane SR, Kulkarni AS (2005) Anti-inflammatory activity of extracts of *Pterocarpus marsupium* and *Coccolina indica*. Indian Drugs 42(5):319
55. Perera HKI (2016) Antidiabetic effects of *Pterocarpus marsupium* Roxb. Medicinal Plant Research 5(3):1–6. https://doi.org/10.3390/mpsr.2015.05.0003
56. Nagarwal RC, Singh PN, Kant S, Matti P, Pandit JK (2011) Chitosan nanoparticles of 5-fluourouracil for ophthalmic delivery: characterization, in vitro and in-vivo study. Chem Pharm Bull 59(2):272–278. https://doi.org/10.1248/cpb.59.272
57. Londonkar RL, Aruna LH, Kanjikar AP (2017) Potential investigation of in vitro Antioxidant, Anti-Inflammatory and Anti-Haemolitic Activities from Polar Solvent Extracts of *Pterocarpus marsupium*. International Journal of Pharmacognosy and Phytochemical Research 9(1):100–107
58. Ahmad H, Rajagopal K (2015) Pharmacology of *Pterocarpus marsupium* Roxb. Medicinal Plant Research 5(3):1–6. https://doi.org/10.3390/mpsr.2015.05.0003
59. Rajeeb M, Usman M, Pathan EK, Jain BV, Pavar SR (2018) Ethnobotanical Uses, Phytochemistry and Pharmacological Activities of *Pterocarpus marsupium*. A review of Ph and Sci innov 2012:1–5. https://doi.org/10.5530/jjpn.2018.6s.1
60. Halagappa K, Girish HN, Srinivasan BP (2010) The study of aqueous extract of *Pterocarpus marsupium* Roxb. on cytokine TNF-α in type 2 diabetic rats. Indian J Pharm 42(6):392–396
61. Phongpradist R, Chaiyana W, Anuchapreeda S (2015) Curcumin-loaded multi-valent ligands conjugated-nanoparticles for anti-inflammatory activity. Int J Pharm Pharm Sci 7(Suppl 4):203–208
62. Sangeetha G, Vidhya R (2016) In vitro anti-inflammatory activity of different parts of Pedalium murex (L) Int J Herb Med 4 Suppl 3:31–36.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Submit your manuscript to a SpringerOpen journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright